This paper discusses the possible therapeutic effects of lipid peroxidation inhibitors, iron complexing agents, and GPX4-GSH-cysteine axis protectors for patients based on the potential connection between COVID-19 complications and ferroptosis. The gene discussed is GPX4; the disease is COVID-19.